For the year ending 2025-12-31, RCEL had -$3,807K decrease in cash & cash equivalents over the period. -$32,200K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 71,610 |
| Purchases of inventory | 10,939 |
| Other cost of sales | 1,855 |
| Gross profit | 58,816 |
| Sales and marketing | 53,138 |
| General and administrative | 27,373 |
| Research and development | 20,839 |
| Total operating expenses | 101,350 |
| Operating loss | -42,534 |
| Interest expense | 5,004 |
| Other income, net | -1,038 |
| Loss before income taxes | -48,576 |
| Income tax expense | 11 |
| Net loss | -48,587 |
| Fair value of common stock issued related to loan amendment | 2,152 |
| Change in fair value of long-term debt | 1,322 |
| Change in fair value of warrant liability | -2,189 |
| Depreciation and amortization | 2,347 |
| Stock-based compensation | 9,519 |
| Non-cash lease expense | 890 |
| Loss on fixed asset disposal | -595 |
| Loss on patent disposal | 11 |
| Remeasurement and foreign currency transaction loss | -17 |
| Excess and obsolete inventory related charges | -810 |
| Provision for credit losses | -10 |
| Amortization of premium of marketable securities | -308 |
| Non-cash changes in the fair value of nqdc plan | 1,203 |
| Trade and other receivables | 3,633 |
| Prepaids and other current assets | -766 |
| Inventory | 468 |
| Operating lease liability | -905 |
| Corporate-owned life insurance ('coli') asset | -406 |
| Other long-term assets | 65 |
| Accounts payable and accrued expenses | 2,745 |
| Accrued wages and fringe benefits | -2,638 |
| Current non-qualified deferred compensation liability | -1,802 |
| Other current liabilities | -81 |
| Non-qualified deferred compensation plan liability | 1,881 |
| Contract liabilities | -33 |
| Net cash used in operating activities | -31,195 |
| Purchase of marketable securities | 13,309 |
| Maturities of marketable securities | 27,500 |
| Purchase of plant and equipment | 1,005 |
| Capitalized software development costs | 635 |
| Patent filing fees | 99 |
| Net cash provided by investing activities | 12,452 |
| Proceeds from private placement of common stock | 14,792 |
| Issuance costs associated with private placement | 1,058 |
| Proceeds from exercise of stock options | 407 |
| Employee stock purchase plan ('espp') purchases | 795 |
| Net cash provided by financing activities | 14,936 |
| Net decrease in cash and cash equivalents | -3,807 |
| Cash and cash equivalents at beginning of period | 14,050 |
| Cash and cash equivalents at end of period | 10,243 |
AVITA Medical, Inc. (RCEL)
AVITA Medical, Inc. (RCEL)